Optimal Strategies for Comprehensive Target Organ Protection in
Heart Disease and Hypertension

WebCAST

WebCAST CME Disclosure

Please read this notice and click the acknowledgement
at the bottom of the page to continue.

Release Date:

May 25, 2009

Expiration Date:

May 25, 2011

Intended Audience:

Cardiologists, prehospital care providers, critical care physicians and intensivists, hypertension specialists, nephrologists, hospitalists and hospital pharmacists.

Registration:

Enrollment for this WebCAST is complimentary, and clinicians are invited to participate in this CME-certified WebCAST and/or share this invitation with other colleagues, departmental staff members, and healthcare professionals.

Grantor Support:

Supported by an independent educational grant from Novartis Pharmaceuticals.
 

Accreditation Statement:

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of The University of Massachusetts Medical School, Office of CME and CMEducation Resources, LLC. The University of Massachusetts Medical School is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statement:

The University of Massachusetts Medical School designates this educational activity for a maximum of 2.0 AMA PRA Category 1 Credit(s). Physicians should only claim credit commensurate with the extent of their participation in the activity.

Policy on Faculty & Provider Disclosure:

It is the policy of the University of Massachusetts Medical School to ensure fair balance, independence, objectivity and scientific rigor in all activities. All faculty participating in CME activities sponsored by the University of Massachusetts Medical School are required to present evidence-based data, identify and reference off-label product use and disclose all relevant financial relationships with those supporting the activity or others whose products or services are discussed. Faculty disclosure will be provided in the activity materials.

Program Faculty and Disclosures:

Matthew R. Weir, MD – Program Chairman
Professor and Director
Division of Nephrology
University of Maryland School of Medicine
Baltimore, MD

Consultant: Boehringer Ingelheim, Novartis

Michael A. Weber, MD
Professor of Medicine
SUNY Downtown College of Medicine
Brooklyn, NY

Consultant: Boehringer Ingelheim, Daiichi-Sankyo, Forest, Gilead, Merck, Novartis, Takeda
Speaker’s Bureau: Boehringer Ingelheim, BMS, Daiichi-Sankyo, Forest, GSK, Merck, Novartis, Pfizer, Sanofi-Aventis

Carl J. Pepine, MD, MACC
Professor of Medicine
Division of Cardiovascular Medicine
Gainesville, Florida

Consultant: Abbott/Axio DSMB Chair, Angioblast/DSMB member, Boehringer Ingelheim, CV Therapeutics, Forest, Indigo, NicOx, Novartis/Cleveland Clinic DSMB Chair, Pfizer, Takeda, and The Medicines Company/DCRI IARC.
Grant/Research: NHLBI, Baxter, Cardium, Pfizer, Viron, Abbott, AstraZeneca, sanofi-aventis, Schering Plough, Daiichi-Sankyo, Merck, The Medicines Company, GSK, Wyeth, Cardionet, and AtCor.

Bryan Williams, MD, FRCP, FAHA
Professor of Medicine
Department of Cardiovascular Sciences
University of Leicester School of Medicine
United Kingdom

Consultant: Merck, Pfizer, Novartis
Grant/Research: Merck

Educational Objectives:

Participants in this CME-certified WebCAST will:

• Learn the importance of early treatment of patients with high blood pressure, and the importance of treating both systolic and diastolic blood pressure abnormalities.
• Learn, based on evidence and landmark trials, what the role of RAAS inhibition—using multiple mechanisms of action, including ACEI, ARB, and DRI—is for treatment of HBP and associated cardiovascular conditions.
• Learn how to get their patients to blood pressure goals as quickly as possible, using combination therapy, when indicated.
• Learn prescribing strategies that reduce side effects and increase the likelihood of adherence to an antihypertensive drug regimen, with a focus on drugs affecting RAAS blockade through single and multiple mechanistic interfaces.
  
  

Disclaimer:

Copyright © 2009 by Pharmatecture, LLC and CMEducation Resources, LLC All rights reserved.

Reproduction, distribution, or translation without express written permission is strictly prohibited.

Content on this webcast reflects the opinions, output, and analyses of experts, investigators, educators, and clinicians whose activities for, while independent, are commercially supported by the sponsor noted at the start of each activity.
Content on this webcast is not meant to be, nor substitute for national guidelines or recommendations generated by professional, academic societies, colleges, or associations.

Content on this webcast is intended for educational value only. Its contents, analyses, and any recommendation made herein are intended to make scientific information and opinion available to health professionals, to stimulate thought, and further investigation. This webcast is not designed nor is any aspect of the contents here intended to provide advice regarding medical diagnosis or treatment for any individual case. Any decisions regarding diagnosis and/or management of any individual patient or group of patients should be made on individual basis after having consulted appropriate sources, whether they be appropriate consultants and/or guidelines and recommendations issued by national organizations, professional societies, governmental health organizations, or similar bodies. This webcast is not intended for use by the layman.

Opinions expressed herein are not necessarily those of Pharmatecture, LLC, CMEducation Resources, LLC, program supporters or accreditors, but reflect the opinions and analyses of the experts who have authored the material. Mention of products or services does not constitute endorsement. Clinical, legal, financial, and other comments are offered for general guidance only; and professional counsel should be sought for all specific situations.

Copyright © 2009 All rights reserved